GlassScriptPhysician profile
Maya L Ponte
NPI 1982843140
$2,434.86
in general payments reported to CMS, 2019-2025
23 companies · $692 in 2025
The $692 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $222 · 2020: $56.72 · 2021: $80.47 · 2022: $434 · 2023: $418 · 2024: $532 · 2025: $692.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,641.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,641.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $547.56 | 2019-2025 | |
| Janssen Biotech, INC. | $486.18 | 2019-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $296.39 | 2019-2025 | Winlevi, Absorica Ld |
| Incyte Corporation | $210.97 | 2023-2025 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $200.91 | 2023-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $130.57 | 2019-2025 | |
| Dermavant Sciences, INC. | $73.44 | 2023 | Vtama |
| Leo Pharma INC. | $58.09 | 2021-2025 | Adbry, Anzupgo |
| Novartis Pharmaceuticals Corporation | $54.70 | 2024-2025 | |
| Lilly USA, LLC | $48.36 | 2022-2024 | Taltz, Zepbound, Olumiant |
| Lifenet Health | $44.44 | 2025 | Theragenesis Wound Matrix |
| Verrica Pharmaceuticals INC. | $40.95 | 2023-2024 | Ycanth |
| Genentech USA, INC. | $36.18 | 2019-2020 | |
| Arcutis Biotherapeutics, INC. | $33.79 | 2023-2025 | Zoryve |
| Ucb, INC. | $23.69 | 2025 | Bimzelx |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Botanix Sb INC | $20.65 | 2025 | Sofdra |
| Galderma Laboratories, L.P. | $19.21 | 2025 | Nemluvio |
| Pfizer INC. | $18.69 | 2024 | |
| Blueprint Medicines Corporation | $18.68 | 2024 | Ayvakit |
| E.R. Squibb & Sons, L.L.C. | $18.24 | 2024 | Sotyktu |
| Almirall LLC | $18.02 | 2025 | Seysara |
| Biofrontera INC. | $17.93 | 2025 | |
| Misonix INC | $17.22 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maya Ponte listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.